Evidence map›Paper›PMID 39984807›Full record

ArticleBritish journal of haematology2025

Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France.

Alice Corsia, Laure Joseph, Nathanael Beeker, Sandra Manceau, Marine Driessen, Benoit Meunier, Marina Cavazzana, Mathis Collier, Jean-Marc Treluyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease.Hematology. American Society of Hematology. Education Program · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alice CorsiaBiotherapy Department and Clinical Investigation Center, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Paris, France.ORCID https://orcid.org/0000-0002-9388-2422
Laure JosephBiotherapy Department and Clinical Investigation Center, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Nathanael BeekerEA7323, Evaluation thérapeutique et pharmacologie périnatale et pédiatrique, Université Paris Cité, Paris, France.
Sandra ManceauBiotherapy Department and Clinical Investigation Center, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Paris, France.ORCID https://orcid.org/0000-0003-1836-2002
Marine DriessenService de Gynécologie Obstétrique, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Benoit MeunierBiotherapy Department and Clinical Investigation Center, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Marina CavazzanaBiotherapy Department and Clinical Investigation Center, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Mathis CollierEA7323, Evaluation thérapeutique et pharmacologie périnatale et pédiatrique, Université Paris Cité, Paris, France.
Jean-Marc TreluyerEA7323, Evaluation thérapeutique et pharmacologie périnatale et pédiatrique, Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This nationwide cohort study provides a comprehensive overview of maternal and perinatal outcomes associated with sickle cell disease (SCD) during pregnancy. Using the French national health database, all singleton pregnancy-related hospital discharges from 2013 to 2020 in women aged 15-55 (n = 5 752 080) were selected. Of these, 1022 births were to women with SCD, 308 of whom were on long-term treatment, that is, hydroxyurea (HU) and/or transfusion programme. Pregnancies with SCD were more likely to involve pre-eclampsia (9.6% vs. 1.7%; p < 0.001), pulmonary embolism (0.70% vs. 0.02%; p < 0.001), caesarean sections (52.8% vs. 18.2%; p < 0.001) and postpartum haemorrhage (8.3% vs. 4.1%; p < 0.001) compared to pregnancies without SCD. Preterm birth (<37 weeks) was much more common in women with SCD (28.5% vs. 5.6%). Infants born to women with SCD faced greater adverse neonatal outcomes (22.4% vs. 8.0%; p < 0.001). Although untreated SCD was linked to fewer complications than long-term treated SCD, both conditions presented greater risks compared with pregnancies without SCD. Unexpectedly, babies born to women with SCD had a higher incidence of congenital abnormalities (6.3% vs. 3.4%; p < 0.001), not attributed to HU use. Overall, despite advances in SCD management, pregnancy in SCD remains a high-risk condition, for both mothers and babies.

Indexed as

Anemia, Sickle CellPregnancy Complications, HematologicAdolescentAdultFemaleFranceHumansHydroxyureaInfant, NewbornMiddle AgedPre-EclampsiaPregnancyPregnancy OutcomePremature BirthYoung AdultHydroxyureaadverse neonatal outcomeaspirincongenital abnormalitieshydroxyureaperinatal and maternal outcomespre‐eclampsiapregnancyprematuritysickle cell diseasetransfusion

Identifiers

PMID39984807
PMCPMC11985365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.